Based on the Cansino Biologics Inc. stock forecast from 0 analysts, the average analyst target price for Cansino Biologics Inc. is not available over the next 12 months. Cansino Biologics Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cansino Biologics Inc. is Bearish, which is based on 2 positive signals and 10 negative signals. At the last closing, Cansino Biologics Inc.’s stock price was HKD 30.35. Cansino Biologics Inc.’s stock price has changed by -2.72% over the past week, +4.12% over the past month and +34.59% over the last year.
No recent analyst target price found for Cansino Biologics Inc.
No recent average analyst rating found for Cansino Biologics Inc.
Company Overview Cansino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China. Read Less
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vac...Read More
Frequently Asked Questions About Cansino Biologics Inc. (6185:HK) Stock
Stock Target Advisor's fundamental analysis for Cansino Biologics Inc.'s stock is Bearish.
Unfortunately we do not have enough data on 6185:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6185:HK's stock to indicate what its average analyst target is.
6185:HK stock's Price/Earning ratio is 134.23.
Our analysis grades 6185:HK stock's Price / Earning ratio at F. This means that 6185:HK stock's Price/Earning ratio is above 93% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 6185:HK may be a overvalued for its sector.
The last closing price of 6185:HK's stock was HKD 30.35.
The most recent market capitalization for 6185:HK is HKD 12.24B.
Unfortunately we do not have enough analyst data on 6185:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cansino Biologics Inc.'s stock.
As per our most recent records Cansino Biologics Inc. has 1,494 Employees.
Cansino Biologics Inc.'s registered address is 401-420, Biomedical Park, Tianjin, China, 300457.
You can get more information about it from Cansino Biologics Inc.'s website at https://www.cansinotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Cansino Biologics Inc. (6185:HK) Stock
Stock Target Advisor's fundamental analysis for Cansino Biologics Inc.'s stock is Bearish.
Unfortunately we do not have enough data on 6185:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6185:HK's stock to indicate what its average analyst target is.
6185:HK stock's Price/Earning ratio is 134.23.
Our analysis grades 6185:HK stock's Price / Earning ratio at F. This means that 6185:HK stock's Price/Earning ratio is above 93% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 6185:HK may be a overvalued for its sector.
The last closing price of 6185:HK's stock was HKD 30.35.
The most recent market capitalization for 6185:HK is HKD 12.24B.
Unfortunately we do not have enough analyst data on 6185:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cansino Biologics Inc.'s stock.
As per our most recent records Cansino Biologics Inc. has 1,494 Employees.
Cansino Biologics Inc.'s registered address is 401-420, Biomedical Park, Tianjin, China, 300457.
You can get more information about it from Cansino Biologics Inc.'s website at https://www.cansinotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6185:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
